Chris is an experienced geneticist, biochemist, and entrepreneur. He guided the acquisition of Knudra Transgenics by InVivo Biosystems. He participated in raising over $5 M in funding from venture capital. Achieved more than $7 M in non-dilutive funding from SBIRs. Licensed CRISPR technology in 2014 shortly after it was invented. Inventor on 20+ patents. Created more than 40 service product lines. Cultivated a sales and marketing team that achieved more than $10M in market revenue.

Elizabeth Wagner is a life science executive who leverages over 18 years of relationship-building with CROs, labs, consultants and CDMOs to assist startups in progressing their product pipelines. As the former COO of Constant Therapeutics, she led the company to 3 Phase 2 assets (COVID, DMD-associated cardiomyopathy and stroke) and progressed a peptide oral formulation program through GMP production. Her previous experience includes Corporate Development at Cubist Pharmaceuticals, Portfolio Planning at Genentech and Clinical Research at Genzyme.

Sidney (Sid) Norton is a healthcare executive with 25 years of experience in the private, government, and not-for-profit sectors. He currently serves as the CFO of Intermountain Primary Children’s Hospitals. Before joining Intermountain, he served in senior financial and operational roles at Cincinnati Children’s including as VP of the Cancer and Blood Diseases Institute. He also worked for five years with Indiana University Health in several system finance roles. Sid began his career with Lilly where he worked in M&A and corporate strategy. In 2005 he joined the administration of Indiana Governor Mitch Daniels. While in state government, he worked as CFO for the Family and Social Service Administration. Sid has a BA in Economics from Brigham Young University and an MBA from the Kelley School at Indiana University, Bloomington.

Kevin is a distinguished leader in the pharmaceutical and biotechnology industries with more than four decades of experience spanning hospital pharmacy, medical affairs, external engagement, and strategic leadership. Held senior management positions at Immunex and Amgen. He led market introduction of Enbrel, Prolia, EVENITY, and biosimilars. As Director of Global External Engagement for Amgen, Kevin led cross-functional initiatives spanning bone health, dermatology, rheumatology, cardiovascular disease, and respiratory conditions. In his interim role, Kevin brings a values-driven, humble, and service-oriented approach, where he is always seeking to uplift others through mentorship and support.

Krista is experienced in regulatory sciences where in her prior role she worked as Scientific Director at the Critical Path Institute leading biomarker discovery efforts in lysosomal storage disorders for inclusion in FDA trials. Previously, Krista held the roles of Associate Dean for Research at Florida Gulf Coast University and Associate Director for Research for the Division of Adolescent Medicine at University of Alabama at Birmingham in the Department of Pediatrics.

Dwayne is an expert with clinical trial implementation in lysosomal storage disorders and leukemia. He is a Professor Emeritus at University of Toronto. Authored greater than 70 papers in hematopoietic signalling, leukemia and lysosomal storage disorders. Project manager for Phase 1 clinical trial that utilized gene therapy for treatment of Fabry disease. Deep understanding of regulatory challenges in cell and gene therapy space.

Dr. Tetsu Yung is the founder of TETSUNAGI Consulting, Inc., bringing over 20 years of R&D experience, from basic research as a post-doc at the Tokyo Institute of Technology, to oversight of the entire R&D pipeline at Eisai under the CSO, and as project manager and Head of the CTL (Clinical Team Lead) Group at Fortrea Japan until 2023. He holds a PhD in cellular and molecular biology and an MBA in Finance and International Management. Other than English and Japanese, Tetsu is also fluent in Mandarin, French, and Spanish.

Isaac Collette is using his ongoing training at Brigham Young University with emphasis in business planning to help Glafabra identify and recruit venture capital. In this role, Isaac leverages his multi-year experience in investing in public equities and his role as Equity Analyst at Rogue Funds. Isaac also specifically focused on biotechnology sector and was responsible for bringing in Rogue Funds as Glafabra’s lead investor. As a result, he is currently serving on the Board of Directors for Glafabra as part of the investment agreement.